businesswire logo

Akava Therapeutics, Inc. shares recent data suggesting that AKV9 acts on a common mechanism involved in both Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS)

May 6, 2025
Read More

‘Remarkable’ ALS Drug May Also Work on Alzheimer’s

April 9, 2025
Read More
businesswire logo

Akava Therapeutics, Inc. congratulates SAB Chair Dr. Hande Ozdinler, Founder Dr. Richard B. Silverman, and Dr. William Klein on their recent grant of $7.3 million from the National Institute on Aging to investigate AKV9 in neurodegenerative diseases

December 17, 2024
Read More

National Institute on Aging invests an additional $7.3 million into NU-9

November 6, 2024
Read More
businesswire logo

Akava Therapeutics, Inc. Announces FDA Clearance of Investigational New Drug Application for the Treatment of Amyotrophic Lateral Sclerosis

August 22, 2023
Read More
National Academy of Sciences Logo

Richard B. Silverman elected to the National Academy of Sciences

May 16, 2023
Read More
Drug Hunter Logo

Drug Hunter Interview

January 26, 2023
Drug Hunter Flash Talk with Prof. Hande Ozdinler, Ph.D. and Prof. Richard B. Silverman, Ph.D.
Read More
A Long Swim Logo

A Long Swim

January 26, 2023
A Long Swim co-founder and executive director Doug McConnell sits down with Dr. Hande Ozdinler, A Long Swim Director of Science and Associate Professor of Neurology at Northwestern University, and...
Read More

Akava receives Orphan Drug Designation status for AKV9

July 6, 2022
Akava Therapeutics, Inc. announces that on July 6, 2022, orphan drug designation (ODD) status was received for AKV9 for the treatment of amyotrophic lateral sclerosis (ALS) from the U.S. Food...
Read More

ALS drug breakthrough shows promise in animal studies

May 31, 2022
Read More
1 2